ORTX
Income statement / Annual
Last year (2022), Orchard Therapeutics plc's total revenue was $6.99 M,
an increase of 1,346.38% from the previous year.
In 2022, Orchard Therapeutics plc's net income was -$7.88 M.
See Orchard Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$6.99 M
|
$483,000.00
|
$2.60 M
|
$2.51 M
|
$2.08 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$2.43 M |
$226,000.00 |
$857,000.00 |
$805,000.00 |
$422,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
$4.55 M |
$257,000.00 |
$1.74 M |
$1.71 M |
$1.65 M |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.65 |
0.53 |
0.67 |
0.68 |
0.8 |
0 |
0 |
| Research and Development
Expenses |
$25.55 M
|
$23.35 M
|
$93.73 M
|
$117.36 M
|
$205.32 M
|
$32.53 M
|
$16.21 M
|
| General & Administrative
Expenses |
$44.66 M
|
$49.65 M
|
$56.89 M
|
$49.16 M
|
$0.00
|
$5.99 M
|
$3.00 M
|
| Selling & Marketing
Expenses |
$4.14 M
|
$5.26 M
|
$8.09 M
|
$8.06 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.60 M
|
$13.55 M
|
$64.99 M
|
$57.22 M
|
$31.37 M
|
$5.99 M
|
$3.00 M
|
| Other Expenses |
$22.66 M |
$811,000.00 |
$3.41 M |
$1.39 M |
$5.51 M |
-$1.18 M |
$138,000.00 |
| Operating Expenses |
$36.15 M |
$36.90 M |
$158.72 M |
$174.58 M |
$236.69 M |
$38.51 M |
$19.20 M |
| Cost And Expenses |
$38.58 M |
$36.90 M |
$159.57 M |
$175.39 M |
$237.11 M |
$38.51 M |
$19.20 M |
| Interest Income |
$857,000.00 |
$63,000.00 |
$3.19 M |
$7.36 M |
$0.00 |
$0.00 |
$3,000.00 |
| Interest Expense |
$933,000.00 |
$683,000.00 |
$2.33 M |
$1.54 M |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$23.51 M
|
$874,000.00
|
$8.60 M
|
$8.75 M
|
$1.20 M
|
$302,000.00
|
$6,000.00
|
| EBITDA |
-$8.08 M
|
-$35.54 M
|
-$148.38 M
|
-$164.12 M
|
-$235.03 M
|
-$38.21 M
|
-$19.20 M
|
| EBITDA Ratio |
-1.16 |
-73.58 |
-57.18 |
-65.31 |
-113.21 |
0 |
0 |
| Operating Income Ratio
|
-4.52
|
-75.39
|
-60.49
|
-68.79
|
-113.21
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$25.95 M
|
-$3.32 M
|
$4.27 M
|
$7.21 M
|
$5.51 M
|
-$1.18 M
|
$138,000.00
|
| Income Before Tax |
-$9.01 M |
-$36.22 M |
-$152.71 M |
-$165.66 M |
-$229.53 M |
-$39.69 M |
-$19.07 M |
| Income Before Tax Ratio
|
-1.29
|
-75
|
-58.85
|
-65.92
|
-110.56
|
0
|
0
|
| Income Tax Expense |
-$1.13 M |
$125,000.00 |
-$731,000.00 |
-$2.24 M |
$970,000.00 |
$53,000.00 |
$20,000.00 |
| Net Income |
-$7.88 M |
-$36.35 M |
-$151.98 M |
-$163.42 M |
-$230.50 M |
-$39.74 M |
-$19.09 M |
| Net Income Ratio |
-1.13 |
-75.26 |
-58.57 |
-65.03 |
-111.03 |
0 |
0 |
| EPS |
-0.61 |
-2.93 |
-15.28 |
-17.53 |
-102.17 |
-39.37 |
-18.9 |
| EPS Diluted |
-0.61 |
-2.93 |
-15.28 |
-17.53 |
-102.17 |
-39.37 |
-18.9 |
| Weighted Average Shares
Out |
$12.80 M
|
$12.40 M
|
$9.94 M
|
$9.32 M
|
$2.26 M
|
$1.01 M
|
$1.01 M
|
| Weighted Average Shares
Out Diluted |
$12.82 M
|
$12.40 M
|
$9.94 M
|
$9.32 M
|
$2.26 M
|
$1.01 M
|
$1.01 M
|
| Link |
|
|
|
|
|
|
|
